Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of oral sonidegib (LDE225) schedules in adult acute leukemia
2012-004022-21Phase 2Terminated
- Sponsor
- Novartis
- Start
- Mar 2013
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sonidegib in Acute Leukaemia (2 arms), sponsored by Novartis. Primary endpoint: Rate of complete remission (CR) and complete remission with incomplete blood count recovery (CRi). Started Mar 2013; status: terminated.
02
Drugs
sonidegib
03
Conditions
Acute Leukaemia
Beyond the preview
Go deeper on 2012-004022-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004022-21.